Extended Data Fig. 6: Anti-CTLA-4 response in CD8-GsD mice bearing 4MOSC1 tumors.
From: The GPCR–Gαs–PKA signaling axis promotes T cell dysfunction and cancer immunotherapy failure
Tumor growth curve (left panel) and survival plot (right panel) of CD8-GsD mice implanted with 4MOSC1 tumors treated with anti-CTLA-4 with or without DCZ (n = 7 mice per group). Mice were given three doses of tamoxifen before orthotopic tumor implantation and treated with checkpoint inhibitors and DCZ as previously described. Statistical significance was determined by two-way ANOVA. Statistical significance of survival data was calculated by the log-rank test.
